Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer

Burcak Yoldas, Cem Ozer, Ozlem Ozen, Tuba Canpolat, Isilay Dogan, Thomas S. Griffith, Salih Sanlioglu, Levent N. Ozluoglu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC). Methods. Paraffin-embedded tissues from 60 patients with laryngeal SCC and 14 patients with OCSCC were retrospectively analyzed using immunohistochemistry. Results. An increase in decoy-R1 (DcR1) but a decrease in decoy-R2 (DcR2) expression were observed in patients with laryngeal SCC and in patients with OCSCC compared with control individuals with benign lesions. Clinical and pathologic grading revealed distinctive TRAIL and TRAIL receptor profiles in patients with squamous cell carcinoma of the head and neck (SCCHN). Conclusions. TRAIL and a TRAIL receptor expression profile might be useful to follow-up disease progression by virtue of its connection with clinical staging and pathologic grading in patients with laryngeal SCC. © 2010 Wiley Periodicals, Inc. Head Neck, 2010

Original languageEnglish (US)
Pages (from-to)1278-1284
Number of pages7
JournalHead and Neck
Volume33
Issue number9
DOIs
StatePublished - Sep 1 2011

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
TNF-Related Apoptosis-Inducing Ligand Receptors
Head and Neck Neoplasms
Squamous Cell Carcinoma
Mouth
Ligands
Paraffin
Disease Progression
Tumor Necrosis Factor-alpha
Immunohistochemistry
Head
Clinical Trials
Apoptosis

Keywords

  • TRAIL
  • TRAIL receptor
  • clinical and pathologic staging
  • head and neck cancer
  • molecular diagnostics

Cite this

Yoldas, B., Ozer, C., Ozen, O., Canpolat, T., Dogan, I., Griffith, T. S., ... Ozluoglu, L. N. (2011). Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Head and Neck, 33(9), 1278-1284. https://doi.org/10.1002/hed.21598

Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. / Yoldas, Burcak; Ozer, Cem; Ozen, Ozlem; Canpolat, Tuba; Dogan, Isilay; Griffith, Thomas S.; Sanlioglu, Salih; Ozluoglu, Levent N.

In: Head and Neck, Vol. 33, No. 9, 01.09.2011, p. 1278-1284.

Research output: Contribution to journalArticle

Yoldas, B, Ozer, C, Ozen, O, Canpolat, T, Dogan, I, Griffith, TS, Sanlioglu, S & Ozluoglu, LN 2011, 'Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer', Head and Neck, vol. 33, no. 9, pp. 1278-1284. https://doi.org/10.1002/hed.21598
Yoldas, Burcak ; Ozer, Cem ; Ozen, Ozlem ; Canpolat, Tuba ; Dogan, Isilay ; Griffith, Thomas S. ; Sanlioglu, Salih ; Ozluoglu, Levent N. / Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. In: Head and Neck. 2011 ; Vol. 33, No. 9. pp. 1278-1284.
@article{292449540240497aaa31353150b17414,
title = "Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer",
abstract = "Background. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC). Methods. Paraffin-embedded tissues from 60 patients with laryngeal SCC and 14 patients with OCSCC were retrospectively analyzed using immunohistochemistry. Results. An increase in decoy-R1 (DcR1) but a decrease in decoy-R2 (DcR2) expression were observed in patients with laryngeal SCC and in patients with OCSCC compared with control individuals with benign lesions. Clinical and pathologic grading revealed distinctive TRAIL and TRAIL receptor profiles in patients with squamous cell carcinoma of the head and neck (SCCHN). Conclusions. TRAIL and a TRAIL receptor expression profile might be useful to follow-up disease progression by virtue of its connection with clinical staging and pathologic grading in patients with laryngeal SCC. {\circledC} 2010 Wiley Periodicals, Inc. Head Neck, 2010",
keywords = "TRAIL, TRAIL receptor, clinical and pathologic staging, head and neck cancer, molecular diagnostics",
author = "Burcak Yoldas and Cem Ozer and Ozlem Ozen and Tuba Canpolat and Isilay Dogan and Griffith, {Thomas S.} and Salih Sanlioglu and Ozluoglu, {Levent N.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1002/hed.21598",
language = "English (US)",
volume = "33",
pages = "1278--1284",
journal = "Head and Neck Surgery",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer

AU - Yoldas, Burcak

AU - Ozer, Cem

AU - Ozen, Ozlem

AU - Canpolat, Tuba

AU - Dogan, Isilay

AU - Griffith, Thomas S.

AU - Sanlioglu, Salih

AU - Ozluoglu, Levent N.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC). Methods. Paraffin-embedded tissues from 60 patients with laryngeal SCC and 14 patients with OCSCC were retrospectively analyzed using immunohistochemistry. Results. An increase in decoy-R1 (DcR1) but a decrease in decoy-R2 (DcR2) expression were observed in patients with laryngeal SCC and in patients with OCSCC compared with control individuals with benign lesions. Clinical and pathologic grading revealed distinctive TRAIL and TRAIL receptor profiles in patients with squamous cell carcinoma of the head and neck (SCCHN). Conclusions. TRAIL and a TRAIL receptor expression profile might be useful to follow-up disease progression by virtue of its connection with clinical staging and pathologic grading in patients with laryngeal SCC. © 2010 Wiley Periodicals, Inc. Head Neck, 2010

AB - Background. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC). Methods. Paraffin-embedded tissues from 60 patients with laryngeal SCC and 14 patients with OCSCC were retrospectively analyzed using immunohistochemistry. Results. An increase in decoy-R1 (DcR1) but a decrease in decoy-R2 (DcR2) expression were observed in patients with laryngeal SCC and in patients with OCSCC compared with control individuals with benign lesions. Clinical and pathologic grading revealed distinctive TRAIL and TRAIL receptor profiles in patients with squamous cell carcinoma of the head and neck (SCCHN). Conclusions. TRAIL and a TRAIL receptor expression profile might be useful to follow-up disease progression by virtue of its connection with clinical staging and pathologic grading in patients with laryngeal SCC. © 2010 Wiley Periodicals, Inc. Head Neck, 2010

KW - TRAIL

KW - TRAIL receptor

KW - clinical and pathologic staging

KW - head and neck cancer

KW - molecular diagnostics

UR - http://www.scopus.com/inward/record.url?scp=80051743553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051743553&partnerID=8YFLogxK

U2 - 10.1002/hed.21598

DO - 10.1002/hed.21598

M3 - Article

C2 - 21837697

AN - SCOPUS:80051743553

VL - 33

SP - 1278

EP - 1284

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 1043-3074

IS - 9

ER -